Market Snapshot
S&P Futures
3,809.5
Dow Futures
30,868
Nasdaq Futures
11,633.25
argenx SE
(NASDAQ:ARGX)
$378.88
$5.30
1.42%
argenx SE Chart
ARGX Stock Price Today
argenx SE (ARGX) stock rallied over 1.42% intraday to trade at $378.88 a share on NASDAQ. The stock opened with a gain of 4.11% at $371.13 and touched an intraday high of $383.64, rising 1.42% against the last close of $373.58. The stock went to a low of $368.025 during the session.
Stock Snapshot
$373.58
Prev. Close
20.03 Billion
Market Cap
$368.025
Day Low
$371.13
Open
52.86 Million
Number of Shares
$383.64
Day High
-
P/E ratio
-11.46
EPS (TTM)
45.02
Cash Flow per Share
4.09
Free Float in %
57.43
Book Value
389,158
Volume
argenx SE Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2022-06-30 | $371.13 | $383.64 | $368.025 | $378.88 | 387,895 |
| 2022-06-29 | $363.92 | $377 | $360.9 | $373.58 | 414,800 |
| 2022-06-28 | $368.4 | $368.42 | $362 | $364.47 | 261,000 |
| 2022-06-27 | $365.92 | $376.78 | $363.76 | $373.47 | 228,000 |
| 2022-06-24 | $362.47 | $364.83 | $354.103 | $364.35 | 327,400 |
| 2022-06-23 | $354.9 | $365.81 | $352.4 | $364.55 | 232,900 |
| 2022-06-22 | $349.33 | $359.92 | $348.35 | $354.57 | 244,800 |
| 2022-06-21 | $354.5 | $364.37 | $354.34 | $360.21 | 417,200 |
| 2022-06-17 | $333.06 | $355.13 | $333.06 | $349.96 | 566,900 |
| 2022-06-16 | $331.95 | $335.98 | $326.9 | $330.85 | 301,100 |
Contact Details
Company Information
Employees-
Beta0.96
Sales or Revenue528.27 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
About Company
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.A.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Universite Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Frequently Asked Questions
What is the current argenx SE (ARGX) stock price?
argenx SE (NASDAQ: ARGX) stock price is $378.88 as of the last check on Thursday, June 30. During the trading session, ARGX stock reached the peak price of $383.64 while $368.025 was the lowest point it dropped to.
ARGX's industry and sector of operation?
The NASDAQ listed ARGX is part of Biotechnology industry that operates in the broader Health Care sector. argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.
Who are the executives of ARGX?
Prof. Hans de Haard Ir, Ph.D.
Chief Scientific Officer
Mr. Marc Schorpion
Global Head of HR
Dr. Wim Parys M.D.
Chief Medical Officer
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc., MSc
CEO & Exec. Director
What is the ARGX stock price today?
ARGX stock traded closed the last session at $378.88, which is $5.30 or 1.42% lower than its previous close of $373.58. ARGX's current trading price is 51.86% lower than its 52-week high of $377.00 where as its distance from 52-week low of 249.50% is 0.50%.
How many employees does ARGX have?
Number of ARGX employees currently stands at -. ARGX operates from Willemstraat 5, Breda 4811 AH, Netherlands.
Link for ARGX official website?
Official Webiste of $ARGX is: https://www.argenx.com
How do I contact ARGX?
ARGX could be contacted at ARGX operates from Willemstraat 5, Breda 4811 AH, Netherlands, or at phone #31 10 703 8441 and can also be accessed through its website.
How many shares of ARGX are traded daily?
ARGX stock volume for the day was 389,158 shares while in the previous session number of ARGX shares traded was 387,895 . The average number of ARGX shares traded daily for last 3 months was 307.89 Thousands.
How much did ARGX change today?
The percentage change in ARGX stock occurred in the recent session was 1.42% while the dollar amount for the price change in ARGX stock was $5.30.
What price range ARGX stock been trading in?
In the recent session, the day high for ARGX stock was $383.64 while the low for ARGX stock touched on the day was $368.025.
What is the market cap of ARGX currently?
The market value of ARGX currently stands at 20.03 Billion with its latest stock price at $378.88 and 52.86 Million of its shares outstanding.